Serum-based ALYGNSA immunoassay for the prostate cancer biomarker, total prostate-specific antigen (tPSA) |
| |
Authors: | Brian C Mackness Melisenda J McDonald |
| |
Institution: | (1) Biochemistry Program, Department of Chemistry, College of Arts and Sciences, University of Massachusetts Lowell, Lowell, MA 01854, USA; |
| |
Abstract: | Prostate-specific antigen (PSA) is a serum glycoprotein overproduced by the prostate in prostate cancer (≥4 ng/mL in the bloodstream).
An immunoassay for total PSA (tPSA) was developed using the ALYGNSA method to enhance capture antibody orientation and a limit of detection of 0.63 ng/mL
was reported, a limit 15-fold lower than a commercial tPSA ELISA assay. This ALYGNSA assay, however, was performed using only buffer-based proteins and blocking agents (Mackness
et al., Anal Bioanal Chem 396:681–686, 2010). To improve the clinical application of this system, a serum-based tPSA ALYGNSA was developed employing human serum. This assay also resulted in a limit of detection of 0.63 ng/mL of tPSA protein. The findings reported here provide support for the clinical application of this assay for diagnosis, progression,
treatment, and possible recurrence of prostate cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|